-
1
-
-
79952232216
-
Global cancer statistics
-
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
-
(2011)
CA Cancer J Clin
, vol.61
, pp. 69-90
-
-
Jemal, A.1
Bray, F.2
Center, M.M.3
Ferlay, J.4
Ward, E.5
Forman, D.6
-
2
-
-
84892805731
-
Cancer statistics, 2014
-
Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
-
(2014)
CA Cancer J Clin
, vol.64
, pp. 9-29
-
-
Siegel, R.1
Ma, J.2
Zou, Z.3
Jemal, A.4
-
3
-
-
84873527086
-
Treatment of metastatic cervical cancer: Future directions involving targeted agents
-
Diaz-Padilla I, Monk BJ, Mackay HJ, Oaknin A. Treatment of metastatic cervical cancer: future directions involving targeted agents. Crit Rev Oncol Hematol 2013;85:303-14
-
(2013)
Crit Rev Oncol Hematol
, vol.85
, pp. 303-314
-
-
Diaz-Padilla, I.1
Monk, B.J.2
Mackay, H.J.3
Oaknin, A.4
-
4
-
-
78951471907
-
Cervical cancer
-
Greer BE, Koh WJ, Abu-Rustum NR, Apte SM, Campos SM, Chan J, et al. Cervical cancer. J Natl Compr Canc Netw 2010;8:1388-416.
-
(2010)
J Natl Compr Canc Netw
, vol.8
, pp. 1388-1416
-
-
Greer, B.E.1
Koh, W.J.2
Abu-Rustum, N.R.3
Apte, S.M.4
Campos, S.M.5
Chan, J.6
-
5
-
-
0019408691
-
Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: A phase II study of the Gynecologic Oncology Group
-
Thigpen T, Shingleton H, Homesley H, Lagasse L, Blessing J. Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Cancer 1981;48:899-903.
-
(1981)
Cancer
, vol.48
, pp. 899-903
-
-
Thigpen, T.1
Shingleton, H.2
Homesley, H.3
Lagasse, L.4
Blessing, J.5
-
6
-
-
0024747607
-
A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: A Gynecologic Oncology Group study
-
McGuire WP 3rd, Arseneau J, Blessing JA, DiSaia PJ, Hatch KD, Given FT Jr, et al. A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol 1989;7:1462-8.
-
(1989)
J Clin Oncol
, vol.7
, pp. 1462-1468
-
-
McGuire III., W.P.1
Arseneau, J.2
Blessing, J.A.3
Disaia, P.J.4
Hatch, K.D.5
Given Jr., F.T.6
-
7
-
-
0037486920
-
Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: A gynecologic oncology group study
-
Fracasso PM, Blessing JA, Wolf J, Rocereto TF, Berek JS, Waggoner S. Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol 2003;90:177-80.
-
(2003)
Gynecol Oncol
, vol.90
, pp. 177-180
-
-
Fracasso, P.M.1
Blessing, J.A.2
Wolf, J.3
Rocereto, T.F.4
Berek, J.S.5
Waggoner, S.6
-
8
-
-
0029041394
-
Phase II trial of mitomycin-C in squamous cell carcinoma of the uterine cervix: A Gynecologic Oncology Group study
-
Thigpen T, Blessing JA, Gallup DG, Maiman M, Soper JT. Phase II trial of mitomycin-C in squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1995;57:376-9.
-
(1995)
Gynecol Oncol
, vol.57
, pp. 376-379
-
-
Thigpen, T.1
Blessing, J.A.2
Gallup, D.G.3
Maiman, M.4
Soper, J.T.5
-
9
-
-
0024450677
-
Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix: A Gynecologic Oncology Group study
-
Sutton GP, Blessing JA, Adcock L, Webster KD, DeEulis T. Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix: a Gynecologic Oncology Group study. Invest New Drugs 1989;7:341-3.
-
(1989)
Invest New Drugs
, vol.7
, pp. 341-343
-
-
Sutton, G.P.1
Blessing, J.A.2
Adcock, L.3
Webster, K.D.4
Deeulis, T.5
-
10
-
-
0032168956
-
A phase II trial of CPT-11 in recurrent squamous carcinoma of the cervix: A gynecologic oncology group study
-
Look KY, Blessing JA, Levenback C, Kohler M, Chafe W, Roman LD. A phase II trial of CPT-11 in recurrent squamous carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol 1998;70:334-8.
-
(1998)
Gynecol Oncol
, vol.70
, pp. 334-338
-
-
Look, K.Y.1
Blessing, J.A.2
Levenback, C.3
Kohler, M.4
Chafe, W.5
Roman, L.D.6
-
11
-
-
0033959650
-
Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: A Phase II study of the gynecologic oncology group
-
Schilder RJ, Blessing JA, Morgan M, Mangan CE, Rader JS. Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a Phase II study of the gynecologic oncology group. Gynecol Oncol 2000;76:204-7.
-
(2000)
Gynecol Oncol
, vol.76
, pp. 204-207
-
-
Schilder, R.J.1
Blessing, J.A.2
Morgan, M.3
Mangan, C.E.4
Rader, J.S.5
-
12
-
-
0034089496
-
Topotecan in squamous cell carcinoma of the cervix: A phase II study of the Gynecologic Oncology Group
-
Bookman MA, Blessing JA, Hanjani P, Herzog TJ, Andersen WA. Topotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2000;77:446-9.
-
(2000)
Gynecol Oncol
, vol.77
, pp. 446-449
-
-
Bookman, M.A.1
Blessing, J.A.2
Hanjani, P.3
Herzog, T.J.4
Andersen, W.A.5
-
13
-
-
0035281646
-
Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: A Gynecologic Oncology Group Study
-
Curtin JP, Blessing JA, Webster KD, Rose PG, Mayer AR, Fowler WC Jr, et al. Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2001;19:1275-8.
-
(2001)
J Clin Oncol
, vol.19
, pp. 1275-1278
-
-
Curtin, J.P.1
Blessing, J.A.2
Webster, K.D.3
Rose, P.G.4
Mayer, A.R.5
Fowler Jr., W.C.6
-
14
-
-
0029865737
-
Paclitaxel has moderate activity in squamous cervix cancer: A Gynecologic Oncology Group study
-
McGuire WP, Blessing JA, Moore D, Lentz SS, Photopulos G. Paclitaxel has moderate activity in squamous cervix cancer: a Gynecologic Oncology Group study. J Clin Oncol 1996;14:792-5.
-
(1996)
J Clin Oncol
, vol.14
, pp. 792-795
-
-
McGuire, W.P.1
Blessing, J.A.2
Moore, D.3
Lentz, S.S.4
Photopulos, G.5
-
15
-
-
34548437625
-
Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study
-
Gynecologic Oncology Group Study
-
Garcia AA, Blessing JA, Vaccarello L, Roman LD; Gynecologic Oncology Group Study. Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Am J Clin Oncol 2007;30:428-31.
-
(2007)
Am J Clin Oncol
, vol.30
, pp. 428-431
-
-
Garcia, A.A.1
Blessing, J.A.2
Vaccarello, L.3
Roman, L.D.4
-
16
-
-
10044278053
-
Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: A Gynecologic Oncology Group Study
-
Muggia FM, Blessing JA, Waggoner S, Berek JS, Monk BJ, Sorosky J, et al. Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol Oncol 2005;96:108-11.
-
(2005)
Gynecol Oncol
, vol.96
, pp. 108-111
-
-
Muggia, F.M.1
Blessing, J.A.2
Waggoner, S.3
Berek, J.S.4
Monk, B.J.5
Sorosky, J.6
-
17
-
-
0036534291
-
Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: A gynecologic oncology group study
-
Bloss JD, Blessing JA, Behrens BC, Mannel RS, Rader JS, Sood AK, et al. Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2002;20:1832-7.
-
(2002)
J Clin Oncol
, vol.20
, pp. 1832-1837
-
-
Bloss, J.D.1
Blessing, J.A.2
Behrens, B.C.3
Mannel, R.S.4
Rader, J.S.5
Sood, A.K.6
-
18
-
-
23044495279
-
Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: A Gynecologic Oncology Group Study
-
Long HJ 3rd, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2005;23:4626-33.
-
(2005)
J Clin Oncol
, vol.23
, pp. 4626-4633
-
-
Long III., H.J.1
Bundy, B.N.2
Grendys Jr., E.C.3
Benda, J.A.4
McMeekin, D.S.5
Sorosky, J.6
-
19
-
-
70350433286
-
Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: A Gynecologic Oncology Group study
-
Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2009;27:4649-55.
-
(2009)
J Clin Oncol
, vol.27
, pp. 4649-4655
-
-
Monk, B.J.1
Sill, M.W.2
McMeekin, D.S.3
Cohn, D.E.4
Ramondetta, L.M.5
Boardman, C.H.6
-
20
-
-
4143135504
-
Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: A gynecologic oncology group study
-
Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2004;22:3113-9.
-
(2004)
J Clin Oncol
, vol.22
, pp. 3113-3119
-
-
Moore, D.H.1
Blessing, J.A.2
McQuellon, R.P.3
Thaler, H.T.4
Cella, D.5
Benda, J.6
-
21
-
-
0031023552
-
Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: A Gynecologic Oncology Group study
-
Omura GA, Blessing JA, Vaccarello L, Berman ML, Clarke-Pearson DL, Mutch DG, et al. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 1997;15:165-71.
-
(1997)
J Clin Oncol
, vol.15
, pp. 165-171
-
-
Omura, G.A.1
Blessing, J.A.2
Vaccarello, L.3
Berman, M.L.4
Clarke-Pearson, D.L.5
Mutch, D.G.6
-
22
-
-
84894207820
-
Improved survival with bevacizumab in advanced cervical cancer
-
Tewari KS, Sill MW, Long HJ 3rd, Penson RT, Huang H, Ramondetta LM, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 2014;370:734-43.
-
(2014)
N Engl J Med
, vol.370
, pp. 734-743
-
-
Tewari, K.S.1
Sill, M.W.2
Long III., H.J.3
Penson, R.T.4
Huang, H.5
Ramondetta, L.M.6
-
23
-
-
31444440292
-
Nuclear EGFR signalling network in cancers: Linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival
-
Lo HW, Hung MC. Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. Br J Cancer 2006;94:184-8.
-
(2006)
Br J Cancer
, vol.94
, pp. 184-188
-
-
Lo, H.W.1
Hung, M.C.2
-
24
-
-
0033966576
-
In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody
-
Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K, et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000;6:701-8.
-
(2000)
Clin Cancer Res
, vol.6
, pp. 701-708
-
-
Milas, L.1
Mason, K.2
Hunter, N.3
Petersen, S.4
Yamakawa, M.5
Ang, K.6
-
25
-
-
0034084314
-
Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis
-
Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000;6:2166-74.
-
(2000)
Clin Cancer Res
, vol.6
, pp. 2166-2174
-
-
Huang, S.M.1
Harari, P.M.2
-
26
-
-
0033748391
-
Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide
-
Bianco C, Bianco R, Tortora G, Damiano V, Guerrieri P, Montemaggi P, et al. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. Clin Cancer Res 2000;6:4343-50.
-
(2000)
Clin Cancer Res
, vol.6
, pp. 4343-4350
-
-
Bianco, C.1
Bianco, R.2
Tortora, G.3
Damiano, V.4
Guerrieri, P.5
Montemaggi, P.6
-
27
-
-
0032719534
-
Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas
-
Akimoto T, Hunter NR, Buchmiller L, Mason K, Ang KK, Milas L. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 1999;5:2884-90.
-
(1999)
Clin Cancer Res
, vol.5
, pp. 2884-2890
-
-
Akimoto, T.1
Hunter, N.R.2
Buchmiller, L.3
Mason, K.4
Ang, K.K.5
Milas, L.6
-
28
-
-
84862845405
-
Molecularly targeted therapies in cervical cancer: A systematic review
-
Zagouri F, Sergentanis TN, Chrysikos D, Filipits M, Bartsch R. Molecularly targeted therapies in cervical cancer: a systematic review. Gynecol Oncol 2012;126:291-303.
-
(2012)
Gynecol Oncol
, vol.126
, pp. 291-303
-
-
Zagouri, F.1
Sergentanis, T.N.2
Chrysikos, D.3
Filipits, M.4
Bartsch, R.5
-
29
-
-
50149118998
-
Update on novel therapeutic agents for cervical cancer
-
del Campo JM, Prat A, Gil-Moreno A, Perez J, Parera M. Update on novel therapeutic agents for cervical cancer. Gynecol Oncol 2008;110(3 Suppl 2):S72-6.
-
(2008)
Gynecol Oncol
, vol.110
, Issue.3 SUPPL. 2
-
-
del Campo, J.M.1
Prat, A.2
Gil-Moreno, A.3
Perez, J.4
Parera, M.5
-
30
-
-
80051551247
-
Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study
-
Santin AD, Sill MW, McMeekin DS, Leitao MM Jr, Brown J, Sutton GP, et al. Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 2011;122:495-500.
-
(2011)
Gynecol Oncol
, vol.122
, pp. 495-500
-
-
Santin, A.D.1
Sill, M.W.2
McMeekin, D.S.3
Leitao Jr., M.M.4
Brown, J.5
Sutton, G.P.6
-
31
-
-
78751582338
-
Cetuximab monotherapy in advanced cervical cancer: A retrospective study with five patients
-
Hertlein L, Lenhard M, Kirschenhofer A, Kahlert S, Mayr D, Burges A, et al. Cetuximab monotherapy in advanced cervical cancer: a retrospective study with five patients. Arch Gynecol Obstet 2011; 283:109-13.
-
(2011)
Arch Gynecol Obstet
, vol.283
, pp. 109-113
-
-
Hertlein, L.1
Lenhard, M.2
Kirschenhofer, A.3
Kahlert, S.4
Mayr, D.5
Burges, A.6
-
32
-
-
79955481029
-
Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: A Gynecologic Oncology Group study
-
Farley J, Sill MW, Birrer M, Walker J, Schilder RJ, Thigpen JT, et al. Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study. Gynecol Oncol 2011;121:303-8.
-
(2011)
Gynecol Oncol
, vol.121
, pp. 303-308
-
-
Farley, J.1
Sill, M.W.2
Birrer, M.3
Walker, J.4
Schilder, R.J.5
Thigpen, J.T.6
-
33
-
-
62749156047
-
Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial
-
Kurtz JE, Hardy-Bessard AC, Deslandres M, Lavau-Denes S, Largillier R, Roemer-Becuwe C, et al. Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: a phase II GINECO trial. Gynecol Oncol 2009;113:16-20.
-
(2009)
Gynecol Oncol
, vol.113
, pp. 16-20
-
-
Kurtz, J.E.1
Hardy-Bessard, A.C.2
Deslandres, M.3
Lavau-Denes, S.4
Largillier, R.5
Roemer-Becuwe, C.6
-
34
-
-
37449004176
-
A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer
-
Goncalves A, Fabbro M, Lhomme C, Gladieff L, Extra JM, Floquet A, et al. A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecol Oncol 2008;108:42-6.
-
(2008)
Gynecol Oncol
, vol.108
, pp. 42-46
-
-
Goncalves, A.1
Fabbro, M.2
Lhomme, C.3
Gladieff, L.4
Extra, J.M.5
Floquet, A.6
-
35
-
-
58149151263
-
Phase I trial of erlotinib combined with cisplatin and radiotherapy for patients with locally advanced cervical squamous cell cancer
-
Nogueira-Rodrigues A, do Carmo CC, Viegas C, Erlich F, Camisao C, Fontao K, et al. Phase I trial of erlotinib combined with cisplatin and radiotherapy for patients with locally advanced cervical squamous cell cancer. Clin Cancer Res 2008;14:6324-9.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 6324-6329
-
-
Nogueira-Rodrigues, A.1
do Carmo, C.C.2
Viegas, C.3
Erlich, F.4
Camisao, C.5
Fontao, K.6
-
36
-
-
69449086850
-
A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study
-
Schilder RJ, Sill MW, Lee YC, Mannel R. A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Int J Gynecol Cancer 2009;19:929-33.
-
(2009)
Int J Gynecol Cancer
, vol.19
, pp. 929-933
-
-
Schilder, R.J.1
Sill, M.W.2
Lee, Y.C.3
Mannel, R.4
-
37
-
-
77955874058
-
Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer
-
Monk BJ, Mas Lopez L, Zarba JJ, Oaknin A, Tarpin C, Termrungruanglert W, et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol 2010;28:3562-9.
-
(2010)
J Clin Oncol
, vol.28
, pp. 3562-3569
-
-
Monk, B.J.1
Mas, L.L.2
Zarba, J.J.3
Oaknin, A.4
Tarpin, C.5
Termrungruanglert, W.6
-
38
-
-
27144469023
-
Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix
-
Lee CM, Shrieve DC, Zempolich KA, Lee RJ, Hammond E, Handrahan DL, et al. Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix. Gynecol Oncol 2005;99:415-21.
-
(2005)
Gynecol Oncol
, vol.99
, pp. 415-421
-
-
Lee, C.M.1
Shrieve, D.C.2
Zempolich, K.A.3
Lee, R.J.4
Hammond, E.5
Handrahan, D.L.6
-
39
-
-
79958861740
-
Novel chemotherapy using histone deacetylase inhibitors in cervical cancer
-
Takai N, Kira N, Ishii T, Nishida M, Nasu K, Narahara H. Novel chemotherapy using histone deacetylase inhibitors in cervical cancer. Asian Pac J Cancer Prev 2011;12:575-80.
-
(2011)
Asian Pac J Cancer Prev
, vol.12
, pp. 575-580
-
-
Takai, N.1
Kira, N.2
Ishii, T.3
Nishida, M.4
Nasu, K.5
Narahara, H.6
-
40
-
-
0036527775
-
Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer
-
Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002;1:287-99.
-
(2002)
Nat Rev Drug Discov
, vol.1
, pp. 287-299
-
-
Johnstone, R.W.1
-
41
-
-
30344477367
-
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
-
Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6:38-51.
-
(2006)
Nat Rev Cancer
, vol.6
, pp. 38-51
-
-
Minucci, S.1
Pelicci, P.G.2
-
42
-
-
34447304130
-
Valproic acid (VPA) in patients with refractory advanced cancer: A dose escalating phase I clinical trial
-
Atmaca A, Al-Batran SE, Maurer A, Neumann A, Heinzel T, Hentsch B, et al. Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer 2007;97:177-82.
-
(2007)
Br J Cancer
, vol.97
, pp. 177-182
-
-
Atmaca, A.1
Al-Batran, S.E.2
Maurer, A.3
Neumann, A.4
Heinzel, T.5
Hentsch, B.6
-
43
-
-
26844505068
-
Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer: A phase I study
-
Chavez-Blanco A, Segura-Pacheco B, Perez-Cardenas E, Taja- Chayeb L, Cetina L, Candelaria M, et al. Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer: a phase I study. Mol Cancer 2005;4:22.
-
(2005)
Mol Cancer
, vol.4
, pp. 22
-
-
Chavez-Blanco, A.1
Segura-Pacheco, B.2
Perez-Cardenas, E.3
Taja-Chayeb, L.4
Cetina, L.5
Candelaria, M.6
-
44
-
-
84655175030
-
A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer: Preliminary results
-
Coronel J, Cetina L, Pacheco I, Trejo-Becerril C, Gonzalez-Fierro A, de la Cruz-Hernandez E, et al. A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer: preliminary results. Med Oncol 2011;28 Suppl 1:S540-6.
-
(2011)
Med Oncol
, vol.28
, Issue.SUPPL. 1
-
-
Coronel, J.1
Cetina, L.2
Pacheco, I.3
Trejo-Becerril, C.4
Gonzalez-Fierro, A.5
de la Cruz-Hernandez, E.6
-
45
-
-
77956123071
-
Epigenetic therapy and cisplatin chemoradiation in FIGO stage IIIB cervical cancer
-
Candelaria M, Cetina L, Perez-Cardenas E, de la Cruz-Hernandez E, Gonzalez-Fierro A, Trejo-Becerril C, et al. Epigenetic therapy and cisplatin chemoradiation in FIGO stage IIIB cervical cancer. Eur J Gynaecol Oncol 2010;31:386-91.
-
(2010)
Eur J Gynaecol Oncol
, vol.31
, pp. 386-391
-
-
Candelaria, M.1
Cetina, L.2
Perez-Cardenas, E.3
de la Cruz-Hernandez, E.4
Gonzalez-Fierro, A.5
Trejo-Becerril, C.6
-
46
-
-
0036632368
-
The phosphatidylinositol 3-Kinase AKT pathway in human cancer
-
Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
-
(2002)
Nat Rev Cancer
, vol.2
, pp. 489-501
-
-
Vivanco, I.1
Sawyers, C.L.2
-
47
-
-
84861690519
-
Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer
-
Diaz-Padilla I, Duran I, Clarke BA, Oza AM. Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer. Cancer Treat Rev 2012;38:767-75.
-
(2012)
Cancer Treat Rev
, vol.38
, pp. 767-775
-
-
Diaz-Padilla, I.1
Duran, I.2
Clarke, B.A.3
Oza, A.M.4
-
48
-
-
38149108890
-
All roads lead to mTOR: Integrating inflammation and tumor angiogenesis
-
Lee DF, Hung MC. All roads lead to mTOR: integrating inflammation and tumor angiogenesis. Cell Cycle 2007;6:3011-4.
-
(2007)
Cell Cycle
, vol.6
, pp. 3011-3014
-
-
Lee, D.F.1
Hung, M.C.2
-
49
-
-
70349741010
-
Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin
-
Liu D, Hou P, Liu Z, Wu G, Xing M. Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin. Cancer Res 2009;69:7311-9.
-
(2009)
Cancer Res
, vol.69
, pp. 7311-7319
-
-
Liu, D.1
Hou, P.2
Liu, Z.3
Wu, G.4
Xing, M.5
-
51
-
-
77953711939
-
MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil
-
Hirai H, Arai T, Okada M, Nishibata T, Kobayashi M, Sakai N, et al. MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol Ther 2010;9:514-22.
-
(2010)
Cancer Biol Ther
, vol.9
, pp. 514-522
-
-
Hirai, H.1
Arai, T.2
Okada, M.3
Nishibata, T.4
Kobayashi, M.5
Sakai, N.6
-
52
-
-
0042698478
-
Therapeutic exploitation of checkpoint defects in cancer cells lacking p53 function
-
Dixon H, Norbury CJ. Therapeutic exploitation of checkpoint defects in cancer cells lacking p53 function. Cell Cycle 2002;1:362-8.
-
(2002)
Cell Cycle
, vol.1
, pp. 362-368
-
-
Dixon, H.1
Norbury, C.J.2
-
53
-
-
16544392882
-
Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis
-
Wang Y, Decker SJ, Sebolt-Leopold J. Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis. Cancer Biol Ther 2004;3:305-13.
-
(2004)
Cancer Biol Ther
, vol.3
, pp. 305-313
-
-
Wang, Y.1
Decker, S.J.2
Sebolt-Leopold, J.3
-
54
-
-
84859478908
-
Notch signaling pathway and cancer metastasis
-
Hu YY, Zheng MH, Zhang R, Liang YM, Han H. Notch signaling pathway and cancer metastasis. Adv Exp Med Biol 2012;727:186-98.
-
(2012)
Adv Exp Med Biol
, vol.727
, pp. 186-198
-
-
Hu, Y.Y.1
Zheng, M.H.2
Zhang, R.3
Liang, Y.M.4
Han, H.5
-
55
-
-
78951481235
-
Role of Notch and its oncogenic signaling crosstalk in breast cancer
-
Guo S, Liu M, Gonzalez-Perez RR. Role of Notch and its oncogenic signaling crosstalk in breast cancer. Biochim Biophys Acta 2011; 1815:197-213.
-
(2011)
Biochim Biophys Acta
, vol.1815
, pp. 197-213
-
-
Guo, S.1
Liu, M.2
Gonzalez-Perez, R.R.3
-
56
-
-
67650660754
-
The Notch signaling pathway: Transcriptional regulation at Notch target genes
-
Borggrefe T, Oswald F. The Notch signaling pathway: transcriptional regulation at Notch target genes. Cell Mol Life Sci 2009;66:1631-46.
-
(2009)
Cell Mol Life Sci
, vol.66
, pp. 1631-1646
-
-
Borggrefe, T.1
Oswald, F.2
-
57
-
-
0032242705
-
Notch signalling and the control of cell fate choices in vertebrates
-
Lewis J. Notch signalling and the control of cell fate choices in vertebrates. Semin Cell Dev Biol 1998;9:583-9.
-
(1998)
Semin Cell Dev Biol
, vol.9
, pp. 583-589
-
-
Lewis, J.1
-
58
-
-
0032574857
-
Notch signalling: A short cut to the nucleus
-
Lewis J. Notch signalling: a short cut to the nucleus. Nature 1998; 393:304-5.
-
(1998)
Nature
, vol.393
, pp. 304-305
-
-
Lewis, J.1
-
59
-
-
0029065486
-
Developmental genetics: The Notch connection
-
Simpson P. Developmental genetics: the Notch connection. Nature 1995;375:736-7
-
(1995)
Nature
, vol.375
, pp. 736-737
-
-
Simpson, P.1
-
60
-
-
0030927183
-
The link between integration and expression of human papillomavirus type 16 genomes and cellular changes in the evolution of cervical intraepithelial neoplastic lesions
-
Daniel B, Rangarajan A, Mukherjee G, Vallikad E, Krishna S. The link between integration and expression of human papillomavirus type 16 genomes and cellular changes in the evolution of cervical intraepithelial neoplastic lesions. J Gen Virol 1997;78:1095-101.
-
(1997)
J Gen Virol
, vol.78
, pp. 1095-1101
-
-
Daniel, B.1
Rangarajan, A.2
Mukherjee, G.3
Vallikad, E.4
Krishna, S.5
-
61
-
-
0029078323
-
Alterations in Notch signaling in neoplastic lesions of the human cervix
-
Zagouras P, Stifani S, Blaumueller CM, Carcangiu ML, Artavanis- Tsakonas S. Alterations in Notch signaling in neoplastic lesions of the human cervix. Proc Natl Acad Sci U S A 1995;92:6414-8.
-
(1995)
Proc Natl Acad Sci U S A
, vol.92
, pp. 6414-6418
-
-
Zagouras, P.1
Stifani, S.2
Blaumueller, C.M.3
Carcangiu, M.L.4
Artavanis-Tsakonas, S.5
-
62
-
-
50849117455
-
The role of Notch signaling in human cervical cancer: Implications for solid tumors
-
Maliekal TT, Bajaj J, Giri V, Subramanyam D, Krishna S. The role of Notch signaling in human cervical cancer: implications for solid tumors. Oncogene 2008;27:5110-4.
-
(2008)
Oncogene
, vol.27
, pp. 5110-5114
-
-
Maliekal, T.T.1
Bajaj, J.2
Giri, V.3
Subramanyam, D.4
Krishna, S.5
-
63
-
-
64949083563
-
Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90
-
Koga F, Kihara K, Neckers L. Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90. Anticancer Res 2009;29:797-807.
-
(2009)
Anticancer Res
, vol.29
, pp. 797-807
-
-
Koga, F.1
Kihara, K.2
Neckers, L.3
-
64
-
-
21744445069
-
Heat shock proteins in cancer: Diagnostic, prognostic, predictive, and treatment implications
-
Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 2005;10:86-103.
-
(2005)
Cell Stress Chaperones
, vol.10
, pp. 86-103
-
-
Ciocca, D.R.1
Calderwood, S.K.2
-
65
-
-
67651149741
-
Expression of heat shock protein 60 kDa is upregulated in cervical cancer
-
Hwang YJ, Lee SP, Kim SY, Choi YH, Kim MJ, Lee CH, et al. Expression of heat shock protein 60 kDa is upregulated in cervical cancer. Yonsei Med J 2009;50:399-406.
-
(2009)
Yonsei Med J
, vol.50
, pp. 399-406
-
-
Hwang, Y.J.1
Lee, S.P.2
Kim, S.Y.3
Choi, Y.H.4
Kim, M.J.5
Lee, C.H.6
-
66
-
-
77955348541
-
Hsp90 as a gatekeeper of tumor angiogenesis: Clinical promise and potential pitfalls
-
Bohonowych JE, Gopal U, Isaacs JS. Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls. J Oncol 2010; 2010:412985.
-
(2010)
J Oncol
, pp. 412985
-
-
Bohonowych, J.E.1
Gopal, U.2
Isaacs, J.S.3
-
67
-
-
0031826984
-
Expression of heat shock protein 70 and c-myc in cervical carcinoma
-
Abd el All H, Rey A, Duvillard P. Expression of heat shock protein 70 and c-myc in cervical carcinoma. Anticancer Res 1998;18(3A):1533-6.
-
(1998)
Anticancer Res
, vol.18
, Issue.3 A
, pp. 1533-1536
-
-
el Abd, A.H.1
Rey, A.2
Duvillard, P.3
-
68
-
-
9144261127
-
Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity
-
Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A, Markovina S, et al. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res 2003;63:8984-95.
-
(2003)
Cancer Res
, vol.63
, pp. 8984-8995
-
-
Bisht, K.S.1
Bradbury, C.M.2
Mattson, D.3
Kaushal, A.4
Sowers, A.5
Markovina, S.6
-
69
-
-
84891068902
-
The role of PARP inhibitors in the treatment of gynecologic malignancies
-
Reinbolt RE, Hays JL. The role of PARP inhibitors in the treatment of gynecologic malignancies. Front Oncol 2013;3:237.
-
(2013)
Front Oncol
, vol.3
, pp. 237
-
-
Reinbolt, R.E.1
Hays, J.L.2
-
70
-
-
84866911186
-
Present status and problems on molecular targeted therapy of cancer
-
Saijo N. Present status and problems on molecular targeted therapy of cancer. Cancer Res Treat 2012;44:1-10.
-
(2012)
Cancer Res Treat
, vol.44
, pp. 1-10
-
-
Saijo, N.1
-
71
-
-
84875163620
-
Cisplatin resistance associated with PARP hyperactivation
-
Michels J, Vitale I, Galluzzi L, Adam J, Olaussen KA, Kepp O, et al. Cisplatin resistance associated with PARP hyperactivation. Cancer Res 2013;73:2271-80.
-
(2013)
Cancer Res
, vol.73
, pp. 2271-2280
-
-
Michels, J.1
Vitale, I.2
Galluzzi, L.3
Adam, J.4
Olaussen, K.A.5
Kepp, O.6
|